Kappa and lambda light chain proteins--clinical and prognostic significance in patients with multiple myeloma.
In 76 patients with multiple myeloma an independent or combined light chain production at a ratio of kappa (kappa) to lambda (lambda) chains of 43:33 was proved. Two groups of patients were formed depending on the type of the light chain production. They were compared by a number of biological, clinical and biochemical parameters, which demonstrate the frequency and pathogenetic participation of the two light chains in the main syndromes of the disease. The therapeutic response and prognostic value were also estimated. Bence Jones (lambda) chains prevail in men, in the III clinical stage of the disease, in patients with tubular proteinuria and in syndromes indicating an advanced stage of evolution of the main process, in non-reversible azotaemia, hypercalcaemia and hypoalbuminemia. The survival rate in thus group of patients is an average of 7 months shorter in comparison with the BJ (kappa) group (the difference is non-significant). The median survival of patients with BJ (kappa) is 30 months and 21 months for BJ (lambda).
Goranov
S
S
Department of Haematology, Higher Medical Institute, Plovdiv, Bulgaria.
D000368:Aged; D001536:Bence Jones Protein / Q000096:biosynthesis / Q000737:chemistry; D005260:Female; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000096:biosynthesis*; D007146:Immunoglobulin lambda-Chains / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology*; D011379:Prognosis; D011507:Proteinuria / Q000276:immunology
D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D001536:Bence Jones Protein